As recent studies have shown the clinical effectiveness of topical HA formulations in the reduction or prevention of mucositis in cancer patients undergoing chemotherapy [73,74], it is important to better understand the systemic and tumour-specific effect of the CD44–HA axis in clinical settings. The gene discussed is CD44; the disease is cancer.